The optimism and focus on how healthcare companies could take advantage of the new health insurance exchanges has faded over the last few years. Unless they’re radically restructured, their fate does not look good.
Oscar was one of the main companies that wanted to take advantage of the individual exchange, but has also expanded into small business insurance to hedge a bit, as we discuss in our Oscar strategy teardown.
Investors are clearly still bullish since Oscar Health closed a $165M round, valuing the company at $3.2B, up from $2.7B in 2016.
But is the new valuation justified? For expert intelligence clients, we used different metrics and public market comparisons to determine whether Oscar is worth its new valuation. See the analysis here.
Speaking of Oscar
CEO & Co-founder of Oscar Mario Schlosser will join us on stage at Future of Fintech (June 19-21 in NYC).
Also joining us, co-founder & CEO of Google Ventures-backed Clover Health, Vivek Garipalli. Garipalli has brought in new leadership as the Medicare Advantage space heats up. Is Clover’s data-driven approach enough to give it an edge?
Whether these insurance startups can actually take on entrenched players is one of the most debated topics in digital health. We look forward to hearing them speak.